Praxis Precision Medicines to Participate in Upcoming Investor Conferences


CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that management will participate in the following upcoming virtual investor conferences:

Excerpt from:
Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Related Posts